Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
لماذا يهم هذا الخبر؟
سيظهر الملخص التحليلي هنا بعد اكتمال معالجة الذكاء الاصطناعي.
سياق الخبر
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
فتح الخبر الأصلي